ADC Therapeutics (ADCT) Cash & Equivalents (2019 - 2026)

ADC Therapeutics (ADCT) has reported Cash & Equivalents for 8 consecutive years, with $231.0 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents rose 18.65% year-over-year to $231.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231.0 million (up 18.65% YoY) and the FY2025 annual result came in at $261.3 million, up 4.17% from the prior year.
• Cash & Equivalents fell to $231.0 million in Q1 2026 per ADCT's latest filing, from $261.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ADCT reached as high as $430.9 million in Q1 2022 and fell as low as $194.7 million in Q1 2025.
• A 5-year average of $294.6 million and a median of $278.6 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 30.03% — and 2026, when it rose 18.65%.
• Year by year, Cash & Equivalents stood at $326.4 million in 2022, then dropped by 14.66% to $278.6 million in 2023, then dropped by 9.95% to $250.9 million in 2024, then rose by 4.17% to $261.3 million in 2025, then decreased by 11.61% to $231.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $231.0 million, $261.3 million, and $234.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.